Form 4: CG Oncology Director James Mulay Granted Stock Options Valued at $26.63 Per Share

CG Oncology, Inc. Director James Mulay was granted 24,165 stock options with an exercise price of $26.63 per share, vesting monthly over a year or upon the next annual meeting.

Summary

• James Mulay, a Director of CG Oncology, Inc. (CGON), was granted 24,165 Director Stock Options.
• The options have an exercise price of $26.63 per share.
• The grant date for these options is June 5, 2025.
• The options are set to expire on June 4, 2035.
• Vesting occurs monthly, with 1/12th of the total shares vesting each month following the June 5, 2025 grant date.
• An accelerated vesting clause states that any remaining unvested portion will vest on the date of the Issuer's next annual meeting of stockholders if it occurs prior to the first anniversary of the grant date.
• Vesting is contingent upon Mr. Mulay's continuous service to CG Oncology, Inc. through each vesting date.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant new positive or negative developments for the company itself.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The establishment of a Rule 10b5-1(c) plan indicates a pre-arranged and transparent approach to insider transactions.

Future Outlook

The vesting schedule of the stock options implies an expectation of continued service from Director James Mulay for at least the next 12 months, or until the next annual shareholder meeting, aligning his future compensation with the company's performance.

Management Comments

• The filing was signed by Joshua F. Patterson, Attorney-in-Fact for James Mulay, indicating the formal reporting of the transaction.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a key component of executive and director compensation packages designed to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, typically over one to four years, is also common, designed to retain talent and incentivize sustained performance.
• The use of a Rule 10b5-1 plan for such transactions is a best practice for insiders to manage their equity holdings in a compliant and transparent manner, reducing concerns about insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: While not directly impacting all employees, such compensation structures for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• James Mulay's continued service to CG Oncology, Inc. is required for the stock options to vest according to the established schedule.

Key Dates

Keywords

CG Oncology, CGON, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Rule 10b5-1